LIFEGENE-BIOMARKS, INC.
Medtech · Private
DNA methylation biomarker test for cervical cancer screening in self-collected vaginal swabs
- Grants
- $7.4M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 1
- 0 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Precision methylation biomarkers linked to cancer disparities | $206,042 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision methylation biomarkers linked to cancer disparities | $802,513 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision methylation biomarkers linked to cancer disparities | $733,762 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America | $399,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision DNA methylation test to reduce oral cancer disparities in African Americans patients residing in low-resource settings | $292,486 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas | $275,767 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas | $1,456,725 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision DNA methylation test to reduce oral cancer disparities in African Americans patients residing in low-resource settings | $912,858 | |
| Federal grant | Department of Health and Human Services · Phase II · Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas | $366,433 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 764 | Strategic Operations, Inc. | — | — |
| 765 | PREVENTA MEDICAL CORPORATION | — | — |
| 766 | Nascent Surgical, LLC | — | $363K |
| 767 | LIFEGENE-BIOMARKS, INC. | — | — |
| 768 | Gnu Company, LLC | — | — |
| 769 | LinkDyn Robotics Inc. | — | — |
| 770 | Wield LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- VIRAL AND HOST BIOMARKERS FOR DETECTION, THERAPEUTIC EFFECTIVENESS, AND MONITORING OF CANCER LINKED TO SARS-CoV-2 AND HUMAN PAPILLOMA VIRUSapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.